Elatec enters into partnership with OSPT Alliance
Mobility solutions for the future Elatec GmbH, one of the world’s leading provider of user…
Year: 2021
Krystal announces its ‘1 billion tree pledge’ to help fight climate emergency
Web-hosting company Krystal to invest in a pledge to protect and plant a total of…
Forsta Receives 2021 Customer Experience Innovation Award from CUSTOMER Magazine
B2B company honoured for the 13th consecutive year for improving customer experience and insights technology…
EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial
Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries…
CDR-Life Announces Expansion of Scientific Advisory Board
Two renowned experts join to advise CDR-Life as the company advances pipeline of novel cancer…
Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA)…
Antiviral Canadian Medical Products deactivate 99.9%+ of COVID-19 in 5 minutes: University of Toronto Testing Lab
I3 BioMedical Laboratories Photo credit: I3 BioMedical Inc. MIRABEL, Quebec, Oct. 26, 2021 (GLOBE NEWSWIRE)…
Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1
MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a…
Immunicum Appoints Lotta Ferm as Chief Financial Officer
Press Release 26 October 2021 Immunicum Appoints Lotta Ferm as Chief Financial Officer Immunicum AB…
Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +5% (cc¹, +6%…
Idorsia announces financial results for the third quarter 2021 – company progressing and launch preparations in key markets well underway
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 26, 2021Idorsia Ltd…
Bone Therapeutics Provides Third Quarter 2021 Business Update
REGULATED INFORMATION Recruitment ALLOB tibial fracture Phase IIb trial slower than anticipated due to pandemic…
Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ENCINITAS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX), a clinical-stage…
AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard
AnaptysBio to receive $250 million upfront cash payment from Sagard Healthcare Royalty Partners Sagard to…
Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award
Biosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category PRINCETON, N.J.,…
89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD’s The Liver Meeting 2021
Data from a new sub-analysis of the Phase 1b/2a study in NASH shows correlation between…
4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
– First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary…
ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) — ADMA Biologics, Inc….
Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)
-Anti-viral nasal drop REVTx-99 has potential to broadly prevent or treat respiratory infections including influenza,…
Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update
CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome…